ATLAS Molecular Pharma has been awarded with one of the prestigious NEOTEC grants (2016 call)

ATLAS Molecular Pharma succeeded with the competitive NEOTEC call (CDTI), obtaining a grant for a total amount of 213.000 EUR during the period 2017-2018. The NEOTEC Program aims to support the creation and consolidation of technology-based companies and it takes into account the creation of new technology and the innovation character of the business initiative.

2017-03-07T19:47:38+00:00March 14th, 2017|News|

A possible pharmacological chaperone for congenital erythropoietic porphyria

The Chassys platform has been successfully applied for the identification of a series of putative pharmacological chaperones for the treatment of congenital erythropoietic porphyria. One of them is currently being validated, with most promising results. See also “Una molécula ‘carabina’ para aplacar la porfiria congénita”.

2017-03-06T11:37:51+00:00March 6th, 2017|News|